Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Toshihiko Saeki"'
Autor:
Toshihiko Saeki
Publikováno v:
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents. 3:363-375
Autor:
Akira Naya, Toshihiko Saeki
Publikováno v:
Expert Opinion on Therapeutic Patents. 14:7-16
Because CC chemokine receptor 3 (CCR3) expression is confined to eosinophils, and such leukocytes play an important role in allergic disorders, identification of CCR3 antagonists represents a logical approach to identifying new treatments for eosinop
Autor:
Akira Naya, Toshihiko Saeki
Publikováno v:
Current Pharmaceutical Design. 9:1201-1208
The selective accumulation and activation of leukocytes in inflamed tissues contributes to the pathogenesis of inflammatory and autoimmune diseases such as infection, rheumatoid arthritis, allergic asthma, atopic dermatitis, and multiple sclerosis. A
Autor:
Kenji Ohwaki, Kazuhito Noguchi, Norikazu Ohtake, Toshihiko Saeki, Kensuke Kobayashi, Akira Naya, Makoto Ishikawa
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 11:1219-1223
In searching for a novel CCR3 receptor antagonist, we designed a library that included a variety of carboxamide derivatives based on the structure of our potent antagonists for human CCR1 and CCR3 receptors, and screened the new compounds for inhibit
Autor:
Yoshikazu Iwasawa, Daisuke Ichikawa, Kazuhito Noguchi, Yufu Sagara, Akira Naya, Norikazu Ohtake, Toshihiko Saeki, Kenji Ohwaki
Publikováno v:
Journal of Medicinal Chemistry. 44:1429-1435
The CC chemokines may play an important role in the pathogenesis of chronic inflammatory diseases including rheumatoid arthritis, and their effects are thought to be mediated through CCR1 receptors. Several nonpeptide CCR1 receptor antagonists that s
Autor:
Kazuhito Noguchi, Kenji Ohwaki, Akira Naya, Kensuke Kobayashi, Toshihiko Saeki, Norikazu Ohtake, Makoto Ishikawa
Publikováno v:
Biochemical and Biophysical Research Communications. 281:779-782
CCR3 is expressed in a variety of leukocyte subsets, especially eosinophils, and may be involved in allergic disorders such as atopic asthma. To clarify the pathophysiological roles of CCR3 in allergic disorders, we developed a nonpeptidyl CCR3 antag
Autor:
Akira Naya, Kenji Ohwaki, Kensuke Kobayashi, Makoto Ishikawa, Toshihiko Saeki, Norikazu Ohtake, Kazuhito Noguchi
Publikováno v:
ChemInform. 32
In searching for a novel CCR3 receptor antagonist, we designed a library that included a variety of carboxamide derivatives based on the structure of our potent antagonists for human CCR1 and CCR3 receptors, and screened the new compounds for inhibit
Autor:
Masaki Ihara, Kiyofumi Ishikawa, Fumiaki Ishida, Kaori Saeki, Toshio Kamei, Mitsuo Yano, Toshihiko Saeki
Publikováno v:
Biochemical Pharmacology. 44:1431-1436
Endothelin (ET)-1 reduced heparin-releasable lipoprotein lipase (LPL) activity in 3T3-L1 adipocytes in a concentration-dependent manner. However, a selective ETB receptor agonist, [Ala1,3,11,15]ET-1, did not act like ET-1. The ET-1-induced decrease i
Publikováno v:
Biochemical and Biophysical Research Communications. 179:286-292
A linear peptide analog of endothelin (ET)-1, [Ala1,3,11,15]ET-1 (4AlaET-1), and its truncated peptide analogs were synthesized to study the structural requirements of ET-1 for the recognition of ETs-nonselective ETB receptors. ET-1 exhibited sub-nan
Autor:
Akira Naya, Toshihiko Saeki, Norikazu Ohtake, Kenji Ohwaki, Kensuke Kobayashi, Makoto Ishikawa, Kazuhito Noguchi
Publikováno v:
ChemInform. 34
The structure activity relationships of novel selective CCR3 receptor antagonists, 2-(benzothiazolylthio)acetamimde derivatives were described. A lead structure (1a) was discovered from the screening of the focused library that was based on the struc